期刊
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019
卷 37, 期 -, 页码 173-200出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-immunol-042617-053402
关键词
neoantigens; T cells; cancer; mutations; immunotherapy; checkpoint blockade
类别
Malignant transformation of cells depends on accumulation of DNA damage. Over the past years we have learned that the T cell-based immune system frequently responds to the neoantigens that arise as a consequence of this DNA damage. Furthermore, recognition of neoantigens appears an important driver of the clinical activity of both T cell checkpoint blockade and adoptive T cell therapy as cancer immunotherapies. Here we review the evidence for the relevance of cancer neoantigens in tumor control and the biological properties of these antigens. We discuss recent technological advances utilized to identify neoantigens, and the T cells that recognize them, in individual patients. Finally, we discuss strategies that can be employed to exploit cancer neoantigens in clinical interventions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据